Neurological Institute

Friday, February 03, 2017

University Hospitals Rainbow Babies & Children’s Hospital opens first stem cell study in patients with cystic fibrosis

CLEVELAND – A 39-year-old man with cystic fibrosis (CF) made history by becoming the first person in the world to receive human adult stem cells in a new research study that researchers hope will someday lead to the development of a therapy to reduce the inflammation and infection caused by CF. 

The pioneering subject in the study is Bob Held from Alliance, Ohio, who received an infusion of cells called allogeneic human mesenchymal stem cells (hMSC), adult stem cells collected from the bone marrow of healthy volunteers.  Mr. Held was diagnosed with CF when he was 16 months old. 

Currently, there is no cure for CF, and life expectancy for patients who survive into adulthood is approximately 41 years of age.

Wednesday, October 12, 2016

UH Neurological Institute researchers part of neuroscience ‘big data’ grant

CLEVELAND – University Hospitals Cleveland Medical Center neurologists and a biostatistics researcher are part of a recently announced big data grant recently awarded to Case Western Reserve University School of Medicine by the National Science Foundation.
Samden Lhatoo, MD, Director of the UH Epilepsy Center, Martha Sajatovic, MD, Director of the UH Neurological and Behavioral Outcomes Research Center, and Curtis Tatsuoka, PhD, Director of Biostatistics in the UH Neurological Institute, will work with Principal Investigator Satya Sahoo, PhD, Assistant Professor of Medical Informatics in the Case Western Reserve Department of Epidemiology and Biostatistics.  Dr. Lhatoo is a Professor of Neurology and Dr. Sajatovic is a Professor of Psychiatry at Case Western Reserve School of Medicine.
Dr. Sahoo was awarded a three-year grant to help researchers more effectively gather, use, and share neuroscience-related data, ultimately leading to better treatments.  He will team with colleagues on using technology to obtain, study, and share large amounts of clinical, cognitive, demographic, genetic, and phenotypic (observable characteristics) data from research on neurologically related diseases, conditions and impairments, according to a news release from Case Western Reserve.  

Wednesday, October 05, 2016

Study reports innovative combination of minimally invasive procedures Laser Interstitial Thermotherapy (LITT) & ‘mini’ craniotomy for treating ‘inoperable’ brain tumors

CLEVELAND – A new paper in the October issue of the journal Neurosurgical Focus finds the use of laser beneficial for the removal of large, “inoperable” glioblastoma (GBM) and other types of brain tumors.  The paper is authored by Andrew Sloan, MD, and colleagues from University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center.  (The paper can be found:  A video abstract about it can be found: )
Dr. Sloan and other investigators at the Case Comprehensive Cancer Center led the first in human trials, published in 2013, of a procedure with laser interstitial thermotherapy (LITT), a minimally invasive approach using a laser to “cook” a tumor through a tiny hole in the scalp and bone and the intra-operative MRI (iMRI) to fine tune the treatment rather than the surgeon’s direct vision.   

Wednesday, August 10, 2016

Phase 3 Alzheimer’s disease clinical trial for potential add-on therapy to Donepezil (Aricept) at University Hospitals

CLEVELAND — University Hospitals Case Medical Center is participating in a Phase III clinical research study, called MINDSET, to evaluate the effectiveness of a potential new treatment option for people with mild-to-moderate Alzheimer’s disease.  The investigational drug, RVT-101, is being tested as an add-on therapy to donepezil (brand name Aricept®). Alan Lerner, MD, Director of the Brain Health and Memory Center at UH, is the principal investigator of the study in Cleveland.
MINDSET is an international, multi-center, double blind, placebo-controlled study designed to evaluate the safety, efficacy and tolerability of RVT-101.  The 24-week trial will compare RVT-101 to placebo in approximately 1,150 people with mild-to-moderate Alzheimer’s disease. All study participants will remain on donepezil therapy during the trial.  

Monday, June 20, 2016

Nicholas Bambakidis, MD, appointed Director of University Hospitals Neurological Institute

CLEVELAND – Neurosurgeon Nicholas Bambakidis, MD, has been appointed Director of the University Hospitals Neurological Institute (NI).  He will be responsible for the development and implementation of clinical operations strategy for the institute and will work with NI Co-director Anthony Furlan, MD, and Warren Selman, MD, Chairman of the Department of Neurological Surgery, on the growth of the institute system-wide.
Dr. Bambakidis will continue in his role as Director of Cerebrovascular and Skull Base Surgery.  He is recognized as an international leader in this field and has published more than 100 articles and book chapters as well as three textbooks.  He has led innovative initiatives related to intracerebral bypass surgery for the treatment of brain aneurysms and vascular malformations and neurointerventional endovascular surgery.  He is also Associate Professor of Neurosurgery at the Case Western Reserve University School of Medicine.

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.